(Information sent by the signatory company)

- Peptone and the Bellinzona Institute of Oncology Research (IOR) announce collaborative research agreement

The collaboration focused on the discovery of new targets in prostate cancer

LONDON and BELLINZONA, Switzerland, Nov. 30, 2023 /PRNewswire/ -- Peptone, a leader in translational biophysics and the design of novel therapies against intrinsically disordered proteins (IDPs), and the Institute of Oncology Research (IOR) today announced the start of a sponsored collaborative research agreement in prostate cancer. The collaboration will focus on the identification and progression of new targets in oncology using translational models to develop innovative medicines for patients suffering from prostate cancer.

"A collaboration with the IOR combines Peptone's unique expertise targeting disordered proteins with the power of generative machine learning, unique structural insights into disordered targets, and patient insights into cancer arising from the seminal work of Professor Alimonti's group at Bellinzona" explained Kamil Tamiola, PhD, CEO of Peptone. "Our collaboration is an excellent example of an efficient technology transfer process and a thriving research and biotechnology ecosystem in Ticino, Switzerland."

Peptone is applying advanced biophysical experimental approaches at the atomic level, including novel ultra-low-latency hydrogen-deuterium exchange mass spectrometry (HDX-MS), supercomputing and generative AI to interrogate and drug intrinsically disordered proteins (IDPs). PDIs are proteins that play an important role in health and disease, but because they lack a fixed structure, they have been untreatable or undruggable with conventional drug discovery approaches.

"Prostate cancer remains a highly prevalent disease with significant unmet clinical needs," said Professor Andrea Alimonti, MD, incoming director and professor of Molecular Oncology at the IOR. "We are delighted to partner with Peptone on this research collaboration focused on the discovery of new targets in prostate cancer. Recent findings from my team demonstrate that advanced prostate cancer is regulated by several intrinsically disordered proteins, many of which can also "control the tumor immune response. Targeting these proteins is a promising approach for this challenging disease."

About PeptonePeptone is a translational biophysics company focused on the discovery of new therapies against diseases caused by intrinsically disordered proteins. IDPs are proteins without a fixed structure that play an important role in health and disease. For more information about Peptone, visit peptone.io.

About IOR BellinzonaThe Cancer Research Institute, created in 2003 in Bellinzona (Switzerland), is affiliated with the Università della Svizzera Italiana (USI). It houses researchers from around the world conducting basic and translational research in oncology with a focus on cancer biology, genomics, molecular oncology and experimental therapeutics. The IOR is located in a new high-tech research building that houses more than 20 different research groups, with state-of-the-art laboratories and facilities. Together with the Institute for Research in Biomedicine (IRB), the IOR is a member of the Bellinzona Institutes of Science (Bios⁺), a recently created non-profit association whose objective is to promote, support and coordinate scientific research and teaching activities of its members.

Photo - https://mma.prnewswire.com/media/2288796...Logo - https://mma.prnewswire.com/media/2223699...

View original content: https://www.prnewswire.com/news-releases/peptone-y-el-instituto-de-investigacion-oncologica-ior-bellinzona-anuncian-un-acuerdo-302002055.html